Alzheimer’s’ Drugs Market Size, Share and Global Trend By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Antagonist, Combination Drugs, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography Forecast till 2030

A progressive, irreversible, neurodegenerative, and fatal disorder that induce the brain cells to be degenerate and die, which is characterized by loss of memory and functional decline of the brain system is known as Alzheimer’s. It is the most common cause of dementia in the geriatric population. Dementia is characterized by a loss of cognitive functioning and behavioral abilities that interferes with a person’s ability to function independently.

The accelerating prevalence of Alzheimer’s disorder worldwide, it's leading to increasing pressure for development of curative treatment for Alzheimer’s patients. Significant efforts are being made to develop new drugs and therapy for Alzheimer’s as there is an urgent need for improved Alzheimer’s treatment.

To gain extensive insights into the market, Request for Customization

Pharmaceutical industries and research institutes are strongly active in studying Alzheimer’s, thus making a strong pipeline for Alzheimer’s drugs, and this is anticipated to expand the market potential of Alzheimer’s drugs during the forecast period.

Global Alzheimer’s drug market growth is being driven by the focus of pharmaceutical companies and research institute in R&D of Alzheimer’s creating a strong pipeline for effective therapy. Furthermore, the rise in prevalence of Alzheimer’s disease is leading to increasing demand of Alzheimer’s drugs, which is expected to drive the global Alzheimer’s drugs market growth during the forecast period.

According to World Health Organization (WHO) currently, 50 million people are affected by dementia, and the number is expected to increase during the forecast period.

On the other side, discontinuation of clinical trials of Alzheimer’s drugs by major pharmaceutical companies which is resulting in limited treatment options creating a global economic burden by increasing the nation’s annual treatment cost against Alzheimer’s drugs development and disease treatment which is anticipated to restrain the Alzheimer’s drugs market growth during the forecast period. For example; In March 2019, Biogen and Eisai, Co., Ltd., announced the discontinuation of phase 3 clinical trial of ENGAGE and EMERGE designed evaluate the safety and efficacy in treatment of Alzheimer’s disease.

Key Players Covered

The major companies covered in the global Alzheimer’s drugs market report include F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Eli Lilly and Company., Merck Sharp & Dohme Corp., AstraZeneca, Biogen, AbbVie Inc., ALLERGAN, and other players

SEGMENTATION

As per the current Alzheimer’s drugs market trends, cholinesterase inhibitors among the drug class are most commonly prescribed Alzheimer’s drugs and is anticipated to register a higher market share in the global Alzheimer’s drugs market owing to its effective role in lowering the disease progression.

Key Insights

• Epidemiology of Alzheimer’s disease – For key countries, 2018


• Pipeline analysis


• New product launch


• Overview of key player strategy in development of Alzheimer’s drugs


• Key mergers and acquisitions

Regional Analysis

The global Alzheimer’s drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The global Alzheimer’s drugs market is anticipated to expand in North America during the forecast period owing to growing prevalence of Alzheimer’s disease and presence of global players. According to Alzheimer’s Association, currently, 5.8 million Americans are living with Alzheimer’s, and the number is expected to increase to 14 million by 2050, which is expected to drive the Alzheimer’s drugs market in North America. In Europe, the increasing cases of Alzheimer’s disease, coupled with improving diagnostic capabilities, are projected to augment the Alzheimer’s drugs market by the end of 2026. In Asia Pacific and Latin America, evolving healthcare infrastructure and raising awareness regarding Alzheimer’s disease are anticipated to fuel the Alzheimer’s drugs market growth during the forecast period. Additionally, Alzheimer’s drugs market in Middle East & Africa is in nascent stage; however, unmet needs for Alzheimer’s disease is expected to drive the Alzheimer’s drugs market in this region.

Alzheimer’s Drugs Industry Developments

• In April 2019, the Alzheimer's Drug Discovery Foundation (ADDF), announced a new initiative -Diagnostics Accelerator program that aims to track the development of digital tools for Alzheimer’s disease and dementia.


• In December 2018, Eli Lilly and Company and AC Immune collaborated to develop new treatment for Alzheimer’s disease using AC Immune’s Morphomer platform.